drugset

drugset / Trial / NCT02366637

An Evaluation Of PF-03715455 In Moderate To Severe Chronic Obstructive Pulmonary Disease

NCT02366637 ↗

Phase 2 Terminated 13 enrolled Pfizer

RandomizedCrossoverTriple-blindTreatment

Summary

This study proposes to evaluate the safety and efficacy of PF-03715455 in subjects with moderate to severe Chronic Obstructive Pulmonary Disorder.

Timeline

Start: 2015-01
Primary completion: 2015-05
Completion: 2015-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	PF-03715455	Small molecule	680 ug	Inhaled

Indications